Challenges in managing chronic kidney disease with simultaneous renal transplant immunosuppressant induced buccal squamous cell carcinoma and gastric Burkitt's like lymphoma: A case report

IF 0.2 Q4 ONCOLOGY
Syeda Sara Tajammul , Shruti Maheshwari , Javeria Munir , Khalil Al-Farsi , Ali Allawati , Zamzam Al Hashami , Layth Mula-Hussain
{"title":"Challenges in managing chronic kidney disease with simultaneous renal transplant immunosuppressant induced buccal squamous cell carcinoma and gastric Burkitt's like lymphoma: A case report","authors":"Syeda Sara Tajammul ,&nbsp;Shruti Maheshwari ,&nbsp;Javeria Munir ,&nbsp;Khalil Al-Farsi ,&nbsp;Ali Allawati ,&nbsp;Zamzam Al Hashami ,&nbsp;Layth Mula-Hussain","doi":"10.1016/j.cpccr.2024.100288","DOIUrl":null,"url":null,"abstract":"<div><p>Immunodeficiency is associated with higher cancer incidence, especially in transplanted patients; however, it is unknown whether there is a link between immunodeficiency and the development of multiple primary malignancies. Immunosuppressive drugs may either indirectly potentiate the effect of carcinogens or directly damage the DNA. Skin cancers are the most common malignancies diagnosed in renal transplant recipients. Management of immunosuppression in recipients of transplants who are living with cancer is complex and challenging. A concerted approach between transplant professionals, oncologists, and allied health professionals is therefore needed to ensure optimal care for transplant recipients who are developing immunodeficiency-induced malignancies. Here, we report a challenging case that presented with two simultaneous malignancies (buccal squamous cell carcinoma and gastric Burkitt's-like lymphoma) after nine years of being on immunosuppressants after the kidney transplant. The patient tolerated his cancer treatments with some grade II-III toxicities and is currently a two-year disease-free survivor. Focusing on the curative intent approaches for the two cancers with the adjustment of the immunosuppressant medications, besides the complications associated with these radical treatments, is worthy of being presented to the transplant and oncology teams globally.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000115/pdfft?md5=848d60d4cfd716d236f3f30a83a3b20e&pid=1-s2.0-S2666621924000115-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621924000115","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Immunodeficiency is associated with higher cancer incidence, especially in transplanted patients; however, it is unknown whether there is a link between immunodeficiency and the development of multiple primary malignancies. Immunosuppressive drugs may either indirectly potentiate the effect of carcinogens or directly damage the DNA. Skin cancers are the most common malignancies diagnosed in renal transplant recipients. Management of immunosuppression in recipients of transplants who are living with cancer is complex and challenging. A concerted approach between transplant professionals, oncologists, and allied health professionals is therefore needed to ensure optimal care for transplant recipients who are developing immunodeficiency-induced malignancies. Here, we report a challenging case that presented with two simultaneous malignancies (buccal squamous cell carcinoma and gastric Burkitt's-like lymphoma) after nine years of being on immunosuppressants after the kidney transplant. The patient tolerated his cancer treatments with some grade II-III toxicities and is currently a two-year disease-free survivor. Focusing on the curative intent approaches for the two cancers with the adjustment of the immunosuppressant medications, besides the complications associated with these radical treatments, is worthy of being presented to the transplant and oncology teams globally.

同时患有肾移植免疫抑制剂诱发的口腔鳞状细胞癌和胃伯基特样淋巴瘤的慢性肾病患者的治疗挑战:病例报告
免疫缺陷与较高的癌症发病率有关,特别是在移植患者中;然而,免疫缺陷与多种原发性恶性肿瘤的发生之间是否存在联系尚不清楚。免疫抑制药物可能会间接增强致癌物质的作用或直接损伤 DNA。皮肤癌是肾移植受者中最常见的恶性肿瘤。癌症移植受者的免疫抑制管理既复杂又具有挑战性。因此,移植专业人员、肿瘤专家和专职医疗人员之间需要采取协调一致的方法,以确保为罹患免疫缺陷引起的恶性肿瘤的移植受者提供最佳治疗。在此,我们报告了一个具有挑战性的病例,患者在肾移植后服用免疫抑制剂九年后同时出现两种恶性肿瘤(口腔鳞状细胞癌和胃伯基特样淋巴瘤)。患者能够耐受癌症治疗,但有一些 II-III 级毒性反应,目前无病生存两年。除了与这些根治性治疗相关的并发症之外,重点关注调整免疫抑制剂药物治疗这两种癌症的根治性意图方法值得向全球的移植和肿瘤团队介绍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
0
审稿时长
96 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信